Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Feasibility Study to Determine an Adequate Dose of ICG for the Liver Function Assessment System in Healthy Volunteers

NCT02516319 is registered in ClinicalTrials.gov with Cardiox Corporation as lead sponsor.

NCT NCT02516319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02516319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Feasibility Study to Determine an Adequate Dose of ICG for the Liver Function Assessment System in Healthy Volunteers
Lead sponsor
Cardiox Corporation
Phase
Not applicable
Overall status
Terminated
Start date
September 30, 2012
Completion date
January 31, 2016
Enrollment
57 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic failure